Voyager Therapeutics, Inc. VYGR
- TDP-43 targeting small molecule — Amyotrophic Lateral Sclerosis Preclinical
- TDP-43 targeting small molecule — Frontotemporal Dementia Preclinical
TDP-43 (1 companies · 2 programs)
Companies with an active program directed at TDP-43.